[Criteria for the safety of transfusion of colloidal solutions in patients with acute lung lesions].
The prospective study explored the hemodynamic effects of colloidal solution replacement therapy and the criteria for its safety in patients with acute lung parenchymatous lesions (ALPL) attended by hypoalbuminemia and coagulopathy. There were 68 observations of the effects of colloidal solutions: 20% albumin solution (n=25), freshly frozen plasma (FFP) (n=20), 6% hydroxyethylated starch (HES) 130/0.4 9:1 (n=23). The colloidal solutions were infused at a constant rate; the infusion was stopped until pulmonary wedge pressure (PWP) was 25% greater than its baseline value. Before and after infusion, the parameters of central hemodynamics and oxygen transport, extravascular lung water index (ELWI), pulmonary vascular permeability index (PVPI), and colloid-osmotic pressure (COP) were measured. The infusion volumes were 3.8 +/- 0.4, 13.7 +/- 1.4, and 13.4 +/- 1.3 ml/kg for 20% albumin solution, 6% HES 130/0.4, and FFP, respectively. The PWP-COP gradient increased in all groups. After FFP infusion, there was an increase in ELWI and lung shunt. After 20% albumin solution, there was a delayed increase in ELWI. There was no rise in ELWI after 6% HES administration. In the 20% albumin solution group, the increased ELWI was recorded in patients who had positive baseline PWP-COP gradients (p < 0.05). A combination of higher PVPI and a positive PWP-COP value causes a greater increase in ELWI after 20% albumin solution infusion than in the normal PVPI group. In patients with ALPL, FFP infusion may lead to an increase in the accumulation of extravascular lung water. A negative preinfusion PWP-COP gradient is a safety criterion for the infusion of 20% albumin solution in patients with ALPL. The increased PVPI in combination with a positive PWP-COP gradient is an aggravating factor.
Serebriĭskiĭ
I I
II
Galstian
G M
GM
Borovkova
N B
NB
Gorodetskiĭ
V M
VM
D000208:Acute Disease; D002199:Capillary Permeability; D003102:Colloids / Q000008:administration & dosage / Q000009:adverse effects*; D006438:Hemodilution; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008171:Lung Diseases / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D010100:Oxygen / Q000097:blood; D010952:Plasma Substitutes / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D011659:Pulmonary Gas Exchange; D012449:Safety; D012709:Serum Albumin / Q000378:metabolism; D014882:Water-Electrolyte Balance
D003102:Colloids; D010952:Plasma Substitutes; D012709:Serum Albumin; D010100:Oxygen